Cancer medicines
Polatuzumab vedotin
Polatuzumab vedotin
A CD79b-targeting antibody-drug conjugate for selected B-cell lymphomas.
Sources checked · Introductory guide
On this page
How it works
A CD79b antibody binds the cell and delivers a microtubule-inhibiting drug.[3]
Where it is used
Combined with other medicines in selected DLBCL or high-grade B-cell lymphoma; distinguish initial from relapsed-treatment criteria.[1]
Key safety points
Monitor cytopenias, infection and numbness. Report fever, bleeding, new speech or walking difficulty or confusion immediately.[2]
Questions for your care team
- What medicines make up my regimen, and what nerve and blood monitoring is planned?
Sources and scope
Source documents are in English.
Entries summarize and translate linked official public sources. The source-check date records when those sources were checked; it does not indicate a clinician’s review.
- NCI · Polatuzumab Vedotin-piiq (opens in a new tab)
- MedlinePlus · Polatuzumab Vedotin-piiq (opens in a new tab)
- NCI Drug Dictionary · Polatuzumab Vedotin-piiq (opens in a new tab)
General information based on official public sources. This is not a complete list of uses or side effects. Individual treatment decisions require your care team and current source documents. US-source uses do not establish local approval or reimbursement.